|View printer-friendly version|
Seattle Genetics Announces Business Update Meeting and Webcast
August 16, 2001 at 12:00 AM EDT
Bothell, WA — August 16, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) company management will host a business update meeting on August 21, 2001 at approximately 3:45 p.m. Pacific Time. The session will include presentations on research, development and clinical trial activities. Scheduled presenters include H. Perry Fell, Ph.D., Chief Executive Officer, Clay B. Siegall, Ph.D., President and Chief Scientific Officer and Tim Carroll, Chief Financial Officer.
A webcast of the presentation will be available live and for replay from the Seattle Genetics website, www.seattlegenetics.com, under the “News and Investor Information/audio presentations” section.
About Seattle Genetics
Seattle Genetics discovers and develops monoclonal antibody, or mAb, -based therapeutics to treat cancer and related diseases. The Company has four technologies: engineered mAbs, mAb-drug conjugates, single-chain immunotoxins and antibody-directed enzyme prodrug therapy (ADEPT). Seattle Genetics has built a diverse portfolio of drug candidates targeted to many types of human cancers, including two currently being tested in clinical trials. The Company also out-licenses its mAb-based technologies to strategic partners developing targeted therapies. Seattle Genetics has agreements with many organizations including Genentech, Medarex, Aventis, Bristol-Myers Squibb, Eos Biotechnology, Arizona State University, the University of Miami, and CLB Research and Development. More information about Seattle Genetics can be found at www.seattlegenetics.com.